AffaMed Therapeutics, a global clinical stage biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial…

eTurboNews tala e mo na'o le au fai saofaga. O le lesitala o saʻoloto.
O lo'o fa'aulufale mai iinei Kiliki iinei e lesitala FREE

OA MEA E AVEA MAI LENEI TUSI:

eTurboNews tala e mo na'o le au fai saofaga.
AffaMed Therapeutics, a global clinical stage biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial….
O le lesitala e leai se totogi.